Results from a Phase 1 study indicate that tabalumab in combination with Velcade demonstrates both efficacy and safety in myeloma patients who have relapsed after several previous therapies.

Dr. Nooper Raje from Massachusetts General Hospital in Boston presented the results of the study at the American Society of Hematology (ASH) annual meeting earlier this month. She explained that tabalumab was very promising in this particular patient population, and added that “this was a very well tolerated regimen.”

However, Dr. Raje emphasized that further study of tabalumab at higher doses and in combination …

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …

Results of a Phase 1 clinical trial suggest that the investigational drug LY2127399 in combination with Velcade is safe and effective enough to deserve further study as a potential treatment for multiple myeloma.

“We are very encouraged by these results and would like to move this forward to a randomized trial comparing LY2127399 and Velcade with Velcade alone,” said Dr. Noopur Raje, from Dana-Farber Cancer Institute when she presented these findings at the 47^th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

Dr. Nikhil Munshi from the Dana-Farber …

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

There was a morn­ing session where a total of eight re­search abstracts were pre­sented and discussed.  Then, late in the afternoon, there was an education session focused on mul­ti­ple myeloma, with sev­er­al dif­fer­en­t pre­sen­ta­tions.

The pre­sen­ta­tions during the morn­ing session were on three dif­fer­en­t topics: Revlimid (lena­lido­mide) and its po­ten­tial link to sec­ond­ary cancer; myeloma bone dis­ease; and new drugs being devel­oped as po­ten­tial …

The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago.

More than 30,000 clin­i­cal spe­cialists from all over the world are ex­pected to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. This year’s meeting will primarily focus on the theme of “Patients, Pathways, Progress.”

The meeting will in­clude many pre­sen­ta­tions and seminars focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists over 40 myeloma-based abstracts.

The Myeloma Beacon will be …